<- Go Home
Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
Market Cap
$114.6M
Volume
646.6K
Cash and Equivalents
$21.1M
EBITDA
-$105.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$11.20
52 Week Low
$1.61
Dividend
N/A
Price / Book Value
0.79
Price / Earnings
-1.20
Price / Tangible Book Value
0.79
Enterprise Value
-$38.1M
Enterprise Value / EBITDA
0.36
Operating Income
-$105.3M
Return on Equity
50.77%
Return on Assets
-31.47
Cash and Short Term Investments
$157.5M
Debt
$4.9M
Equity
$144.3M
Revenue
N/A
Unlevered FCF
-$52.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium